Our study highlights the mechanism of FGF2-mediated protection in cisplatin-induced POF and further provides a possible alternative treatment choice via targeting NRF2 for POF patients who are intolerant or unsuitable for FGF2. The gene discussed is FGF2; the disease is premature menopause.